Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ITCINASDAQ:KRTXNYSE:OGNNASDAQ:ROIV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeITCIIntra-Cellular Therapies$131.87$131.73$64.09▼$131.98$14.05B0.691.49 million shsN/AKRTXKaruna Therapeutics$329.83$327.01$158.38▼$329.99$12.58B1.18832,048 shs5 shsOGNOrganon & Co.$8.69-0.2%$12.76$8.05▼$23.10$2.26B0.753.08 million shs9.04 million shsROIVRoivant Sciences$10.99+3.3%$10.49$8.73▼$13.06$7.84B1.235.56 million shs4.86 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceITCIIntra-Cellular Therapies0.00%0.00%0.00%+3.74%+103.00%KRTXKaruna Therapeutics0.00%0.00%0.00%0.00%0.00%OGNOrganon & Co.0.00%-9.17%-21.90%-42.00%-57.30%ROIVRoivant Sciences0.00%-7.23%+8.01%-1.30%-4.31%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationITCIIntra-Cellular Therapies0.6846 of 5 stars1.10.00.04.50.61.70.6KRTXKaruna TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOGNOrganon & Co.4.8754 of 5 stars3.01.03.33.73.23.33.1ROIVRoivant Sciences2.2868 of 5 stars3.51.00.00.04.12.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceITCIIntra-Cellular Therapies 2.17Hold$109.70-16.81% DownsideKRTXKaruna Therapeutics 0.00N/AN/AN/AOGNOrganon & Co. 2.00Hold$18.00107.09% UpsideROIVRoivant Sciences 3.00Buy$17.5059.24% UpsideCurrent Analyst Ratings BreakdownLatest ROIV, OGN, KRTX, and ITCI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2025OGNOrganon & Co.Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $10.005/2/2025OGNOrganon & Co.Evercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Inline4/21/2025ROIVRoivant SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.004/9/2025OGNOrganon & Co.Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$16.00 ➝ $15.004/2/2025ITCIIntra-Cellular TherapiesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$132.00 ➝ $132.003/4/2025ROIVRoivant SciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy2/24/2025ITCIIntra-Cellular TherapiesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$140.00 ➝ $132.002/21/2025ITCIIntra-Cellular TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold2/14/2025OGNOrganon & Co.BarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$26.00 ➝ $24.002/14/2025OGNOrganon & Co.Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$17.00 ➝ $16.00(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookITCIIntra-Cellular Therapies$680.50M20.64N/AN/A$6.15 per share21.44KRTXKaruna Therapeutics$654K19,239.07N/AN/A$33.24 per share9.92OGNOrganon & Co.$6.29B0.36$2.79 per share3.12($0.27) per share-32.19ROIVRoivant Sciences$122.59M63.97N/AN/A$7.76 per share1.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateITCIIntra-Cellular Therapies-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%N/AKRTXKaruna Therapeutics-$433.68M-$11.72N/AN/AN/AN/A-31.63%-30.38%N/AOGNOrganon & Co.$864M$2.882.612.320.9013.49%431.62%8.03%N/AROIVRoivant Sciences$4.35B-$0.15N/AN/AN/A-119.54%-14.05%-12.81%5/29/2025 (Estimated)Latest ROIV, OGN, KRTX, and ITCI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2025Q4 2025ROIVRoivant Sciences-$0.16N/AN/AN/A$62.17 millionN/A5/1/2025Q1 2025OGNOrganon & Co.$0.89$1.02+$0.13$0.33$1.53 billion$1.51 billion2/21/2025Q4 2024ITCIIntra-Cellular Therapies-$0.08-$0.16-$0.08-$0.16$205.08 million$199.22 million2/13/2025Q4 2024OGNOrganon & Co.$0.92$0.83-$0.09$0.42$1.57 billion$1.59 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthITCIIntra-Cellular TherapiesN/AN/AN/AN/AN/AKRTXKaruna TherapeuticsN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.92%+25.99%2.78%N/AROIVRoivant SciencesN/AN/AN/AN/AN/ALatest ROIV, OGN, KRTX, and ITCI DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025OGNOrganon & Co.quarterly$0.020.8%5/12/20255/12/20256/12/20252/13/2025OGNOrganon & Co.quarterly$0.287.3%2/24/20252/24/20253/13/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioITCIIntra-Cellular TherapiesN/A7.667.51KRTXKaruna TherapeuticsN/A19.3119.31OGNOrganon & Co.17.731.701.21ROIVRoivant SciencesN/A37.9137.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipITCIIntra-Cellular Therapies92.33%KRTXKaruna TherapeuticsN/AOGNOrganon & Co.77.43%ROIVRoivant Sciences64.76%Insider OwnershipCompanyInsider OwnershipITCIIntra-Cellular Therapies2.60%KRTXKaruna Therapeutics13.20%OGNOrganon & Co.1.96%ROIVRoivant Sciences7.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableITCIIntra-Cellular Therapies560106.52 million103.56 millionOptionableKRTXKaruna Therapeutics33938.15 million33.16 millionOptionableOGNOrganon & Co.10,000259.96 million253.93 millionNot OptionableROIVRoivant Sciences860713.55 million657.18 millionOptionableROIV, OGN, KRTX, and ITCI HeadlinesRecent News About These CompaniesWho is Vivek Ramaswamy? Ohio Republican Party endorses entrepreneur for governor in 2026May 12 at 5:04 PM | mansfieldnewsjournal.comSchonfeld Strategic Advisors LLC Reduces Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)May 11 at 4:41 AM | marketbeat.comNorthern Trust Corp Boosts Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)May 11 at 4:33 AM | marketbeat.comVivek Ramaswamy Sells 273,959 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) StockMay 11 at 4:14 AM | marketbeat.comDME Capital Management LP Sells 36,973 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)May 10 at 7:19 AM | marketbeat.comSelon un récent dépôt auprès de la SEC, un initié de Roivant Sciences a vendu des actions pour une valeur de 10 129 810 dollars.May 9 at 7:16 PM | zonebourse.comRoivant Sciences Ltd. (NASDAQ:ROIV) Shares Purchased by Caption Management LLCMay 9 at 6:18 AM | marketbeat.comEnvestnet Asset Management Inc. Makes New Investment in Roivant Sciences Ltd. (NASDAQ:ROIV)May 9 at 3:25 AM | marketbeat.comPrice T Rowe Associates Inc. MD Sells 25,367 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)May 8, 2025 | marketbeat.com24,000 Shares in Roivant Sciences Ltd. (NASDAQ:ROIV) Acquired by Bellevue Group AGMay 7, 2025 | marketbeat.com84,091 Shares in Roivant Sciences Ltd. (NASDAQ:ROIV) Purchased by Raymond James Financial Inc.May 7, 2025 | marketbeat.comBaker BROS. Advisors LP Buys 969,057 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)May 6, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Hits New 52-Week High - Time to Buy?May 3, 2025 | marketbeat.comRoivant Sciences Ltd. (ROIV): Among David Einhorn’s Stock Picks with Huge Upside PotentialMay 2, 2025 | insidermonkey.comRoivant Sciences Ltd. (ROIV): Among David Einhorn’s Stock Picks with Huge Upside PotentialMay 2, 2025 | msn.comRoivant Sciences Ltd. (NASDAQ:ROIV) Shares Acquired by PDT Partners LLCMay 1, 2025 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Position Boosted by TOMS Capital Investment Management LPMay 1, 2025 | marketbeat.comRoivant Sciences Ltd. (ROIV): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside PotentialApril 29, 2025 | insidermonkey.comIntegrated Wealth Concepts LLC Purchases 41,564 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)April 29, 2025 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Position Increased by Tower Research Capital LLC TRCApril 29, 2025 | marketbeat.comGilder Gagnon Howe & Co. LLC Acquires Shares of 1,162,986 Roivant Sciences Ltd. (NASDAQ:ROIV)April 28, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeROIV, OGN, KRTX, and ITCI Company DescriptionsIntra-Cellular Therapies NASDAQ:ITCI$131.87 0.00 (0.00%) As of 04/2/2025Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Karuna Therapeutics NASDAQ:KRTXKaruna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Organon & Co. NYSE:OGN$8.69 -0.02 (-0.21%) Closing price 03:59 PM EasternExtended Trading$8.69 0.00 (-0.02%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.Roivant Sciences NASDAQ:ROIV$10.99 +0.35 (+3.29%) Closing price 04:00 PM EasternExtended Trading$10.99 0.00 (0.00%) As of 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
